Mitelos is a B2B company based in Barcelona committed to develop, register, manufacture and supply branded consumer health products. Our core expertise lies in ear care. Indeed, we put our first product on the market in 2016 and now we are present in Europe, Latam, Middle East, Africa and Southeast Asia, with more than 4 million units sold in more than 20 countries.
Our current portfolio is composed of the following products:
OTIBLOCK® ear spray, intended to remove earwax impaction, prevent recurrences and ease the manual removal at healthcare settings when it is required.
For more information, refer to https://otiblock.com/
OTIDRY-MD® ear spray, intended to prevent “swimmer’s ear” (acute otitis externa).
For more information, refer to https://otidry-md.info/
OTIKEEN® fluid emulsion, intended to treat outer ear eczema and itchy ears due to the use of earbuds, earplugs, hearing aids, etc.
For more information, refer to https://otikeen.com/
We are looking for companies:
Mitelos is actively looking for commercial partners to expand its geographical presence on the market with its current portfolio.
We look for long-term collaborations, fostering strong and mutually beneficial relationships.
One of the main advantages of cooperating with Mitelos is our commitment to our partner’s success. Our team provides constant regulatory, commercial and medical support to optimise sales results.
Last, but not least, Mitelos is proactively seeking to acquire products in the Consumer Health market (in any category) that are already registered in Europe or have low sales and that the incumbent company wishes to divest.
How to contact us?
We will be very pleased to meeting you at the Europharm International Business Meeting in Athens on the 10th & 11th April 2025: www.europharmbusinessmeeting.com
Sonia Barrón
Director, Corporate Development
T.+34 935 481 858
sbarron@mitelos.com
Roser Raurich
Business Development Manager
T.+34 935 481 858; C.+34 661794905
rraurich@mitelos.com
Mitelos Bioscience, S.L.
Europham SMC
Connect with us on LinkedIn for the latest updates and insights